



BiOkuris

# Gastrap<sup>®</sup> Direct

Experience relief from gas and bloating and restore a healthy gut microbiota with our unique solution

## GASTRAP<sup>®</sup> DIRECT IS INTENDED TO HELP WITH:

**Regularization** /normalization of intestinal transit and stool evacuation


**Relief** of gas-related symptoms such as bloated feeling, flatulence and abdominal pain

**Normalization** of the intestinal function

## A UNIQUE MECHANISM OF ACTION


### Simethicone

A chemically inert mixture of polydimethylsiloxane and silica (CAS No. 8050-81-5)



### KiOtransine<sup>®</sup>

A novel ingredient derived from mycelium, patented by KitoZyme composed of two types of polysaccharide chains linked in a 3d structure: chitin and beta-glucan.



### Action

Antifoaming effect favoring fast gas elimination

### Action

Effect on stool consistency, stool frequency, quality of evacuation and intestinal flora



Favoring gas elimination



Improving stool consistency





Restoring a balanced microbiota

# EXCEPTIONAL RESULTS VIA MULTIPLE CLINICAL, *IN VITRO*, AND *IN VIVO* STUDIES

GASTRAP® Direct (medical device class IIa) is intended to be used in the symptomatic treatment of gas-related gastro-intestinal disorders


## Clinical study

Clinical benefits in improving symptoms associated with the presence of gas confirmed in post marketing



## Clinical study

Gastrap® Direct and IBS (irritable bowel syndrome)




- Abdominal pain
- Bloating
- Dyschesia and other defecation problems
- Flatulence

## User test

Efficacy on Intestinal troubles vs. competition

Stool symptoms improvement after 1 week



After 4 weeks, decrease of each gastrointestinal symptom intensity in the Gastrap® group: Abdominal pain/discomfort, flatulence, bloating, borborygmi and in a lower range nausea



Proven benefits of simethicone and the long-lasting effect of our prebiotic



**In vivo** PPAR<sub>γ</sub> Results indicate that the significant anti-inflammatory effect observed for Gastrap® may involve at least in part the induction of PPAR<sub>γ</sub>

## About BiOkuris

BiOkuris has developed the next generation of medical nutrition products tailored to the unmet medical needs of patients with chronic intestinal diseases such as IBD, IBS and Candidiasis. BiOkuris is part of the KitoZyme Group.

[www.biokuris.com](http://www.biokuris.com) – [info@biokuris.com](mailto:info@biokuris.com)

© April 2023, BiOkuris – All right reserved. The information contained herein is based on data know to KitoZyme or its affiliates at the time of preparation of the brochure. This is business-to-business information intended for distributors and is not intended for the final users or consumers.

